Dcaf15,也称为DDB1和CUL4相关因子15,是一种重要的E3泛素连接酶复合物中的适配蛋白。DCAF15与DDB1和CUL4结合,形成CRL4-DCAF15 E3泛素连接酶复合物,参与细胞内蛋白质的泛素化和降解。DCAF15在细胞周期的调控、DNA损伤修复和肿瘤的发生发展中发挥重要作用。
DCAF15在肿瘤的发生发展中具有重要作用。研究表明,DCAF15可以与多种肿瘤相关的蛋白相互作用,参与肿瘤的发生和发展。例如,DCAF15可以与ZEB1相互作用,促进上皮-间质转化(EMT)的发生,从而促进肿瘤的侵袭和转移[5]。此外,DCAF15还可以与RBPs(RNA结合蛋白)相互作用,影响RNA的剪接和稳定性,从而影响基因的表达和肿瘤的发生发展[1,2,3,4,6,7,8,9,10]。
DCAF15还可以与多种药物相互作用,影响药物的治疗效果。例如,arylsulfonamides类药物可以与DCAF15结合,促进RBPs的降解,从而影响RNA的剪接和稳定性,进而影响基因的表达和肿瘤的发生发展[1,3,6,8]。此外,DCAF15还可以与PARP抑制剂等药物相互作用,影响药物的治疗效果[7]。
综上所述,DCAF15是一种重要的E3泛素连接酶复合物中的适配蛋白,参与细胞周期的调控、DNA损伤修复和肿瘤的发生发展。DCAF15在肿瘤的发生发展中具有重要作用,可以与多种肿瘤相关的蛋白和药物相互作用,影响肿瘤的发生发展和药物的治疗效果。因此,DCAF15是肿瘤治疗和药物研发的重要靶点之一。
参考文献:
1. Xu, Yuewei, Nijhuis, Anke, Keun, Hector C. 2021. RNA-binding motif protein 39 (RBM39): An emerging cancer target. In British journal of pharmacology, 179, 2795-2812. doi:10.1111/bph.15331. https://pubmed.ncbi.nlm.nih.gov/33238031/
2. Wang, Eric, Lu, Sydney X, Pastore, Alessandro, Abdel-Wahab, Omar, Aifantis, Iannis. 2019. Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. In Cancer cell, 35, 369-384.e7. doi:10.1016/j.ccell.2019.01.010. https://pubmed.ncbi.nlm.nih.gov/30799057/
3. Campagne, Sébastien, Jutzi, Daniel, Malard, Florian, Ruepp, Marc-David, Allain, Frédéric H-T. 2023. Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39. In Nature communications, 14, 5366. doi:10.1038/s41467-023-40254-5. https://pubmed.ncbi.nlm.nih.gov/37666821/
4. Pech, Matthew F, Fong, Linda E, Villalta, Jacqueline E, Jan, Calvin H, Settleman, Jeffrey. 2019. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. In eLife, 8, . doi:10.7554/eLife.47362. https://pubmed.ncbi.nlm.nih.gov/31452512/
5. Dong, Xiao, Han, Yang, Zhang, Encheng, Zhong, Lin, Li, Qi. 2021. Tumor suppressor DCAF15 inhibits epithelial-mesenchymal transition by targeting ZEB1 for proteasomal degradation in hepatocellular carcinoma. In Aging, 13, 10603-10618. doi:10.18632/aging.202823. https://pubmed.ncbi.nlm.nih.gov/33833131/
6. Ting, Tabitha C, Goralski, Maria, Klein, Katherine, Xie, Yang, Nijhawan, Deepak. . Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15. In Cell reports, 29, 1499-1510.e6. doi:10.1016/j.celrep.2019.09.079. https://pubmed.ncbi.nlm.nih.gov/31693891/
7. Xu, Yuewei, Spear, Sarah, Ma, Yurui, Keun, Hector C, Nijhuis, Anke. 2023. Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. In Cell reports, 42, 113307. doi:10.1016/j.celrep.2023.113307. https://pubmed.ncbi.nlm.nih.gov/37858464/
8. Kohsaka, Shinji, Yagishita, Shigehiro, Shirai, Yukina, Hamada, Akinobu, Mano, Hiroyuki. 2024. A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency. In NPJ precision oncology, 8, 117. doi:10.1038/s41698-024-00610-0. https://pubmed.ncbi.nlm.nih.gov/38789724/
9. Kim, Sung Ah, Jo, Seung-Hyun, Cho, Jin Hwa, Kim, Sunhong, Kim, Jeong-Hoon. . Aryl Sulfonamides Induce Degradation of Aryl Hydrocarbon Receptor Nuclear Translocator through CRL4DCAF15 E3 Ligase. In Molecules and cells, 43, 935-944. doi:10.14348/molcells.2020.0122. https://pubmed.ncbi.nlm.nih.gov/33168788/
10. Ji, Tongting, Yang, Yang, Yu, Juanjuan, Pan, Jian, Lu, Jun. 2024. Targeting RBM39 through indisulam induced mis-splicing of mRNA to exert anti-cancer effects in T-cell acute lymphoblastic leukemia. In Journal of experimental & clinical cancer research : CR, 43, 205. doi:10.1186/s13046-024-03130-8. https://pubmed.ncbi.nlm.nih.gov/39044280/